Trial Profile
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of AGN-241751 in Adult Participants With Major Depressive Disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2022
Price :
$35
*
At a glance
- Drugs Zelquistinel (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Allergan
- 23 Jul 2019 Planned End Date changed from 15 Aug 2019 to 18 Aug 2019.
- 23 Jul 2019 Planned primary completion date changed from 19 Jul 2019 to 18 Aug 2019.
- 19 Jul 2019 Status changed to active, no longer recruting.